Comparative Pharmacology
Head-to-head clinical analysis: FENOFIBRATE versus FIBRICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOFIBRATE versus FIBRICOR.
FENOFIBRATE vs FIBRICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
FIBRICOR (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apolipoprotein C-III (an inhibitor of lipoprotein lipase). This leads to decreased triglyceride and increased HDL cholesterol levels.
Fenofibrate: 48-145 mg orally once daily. For fenofibric acid: 45-135 mg orally once daily. Capsules should be taken with meals.
FIBRICOR (fenofibric acid) is dosed as 45 mg or 135 mg orally once daily, with or without food. The typical adult dose is 135 mg daily. For mixed dyslipidemia, the recommended dose is 135 mg once daily; for severe hypertriglyceridemia, start with 45 to 135 mg once daily, titrating based on response.
None Documented
None Documented
Clinical Note
moderateFenofibrate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Fenofibrate."
Clinical Note
moderateFenofibrate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Fenofibrate."
Clinical Note
moderateFenofibrate + Cyclosporine
"Fenofibrate may increase the nephrotoxic activities of Cyclosporine."
Clinical Note
moderateFenofibrate + Fluconazole
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 16-25 hours), allowing once-daily dosing. Steady-state is reached within 5 days.
Terminal elimination half-life is approximately 20 hours (range 19-26 hours) in healthy volunteers, with clinical context indicating that steady state is achieved within 1 week of dosing.
Renal: approximately 60% of the dose as fenofibric acid glucuronide; unchanged fenofibric acid < 10%. Biliary/fecal: approximately 25% as fenofibric acid and conjugates. Renal excretion is predominant.
Approximately 60-70% of the dose is excreted renally as unchanged drug or glucuronide conjugate, and about 20-25% is excreted fecally. Biliary excretion is minimal.
Category A/B
Category C
Fibrate
Fibrate
"The metabolism of Fluconazole can be decreased when combined with Fenofibrate."